Executive Summary
HHS awarded $201M across 9 contracts in this period, dominated by neutral signals (6/9) with steady revenue for utilities, nonprofits, and consultants, but bullish upside in 3 small/mid-cap IT, manufacturing, and consulting plays via unexercised options totaling ~$80M+. Firm fixed price structures (7/9 contracts) pose uniform margin risks amid 66% average outlay progress, while long-tail performance to 2033 signals multi-year health R&D commitment. Investors should prioritize small business winners like Four Points and Acumen for option exercises amid CMS/NIH focus on innovation models.
Tracking the trend? Catch up on the prior All HHS Contracts digest from January 06, 2026.
Investment Signals(3)
- Small biz IT/health tech secures $83M+ with $40M options(HIGH)▲
Four Points, Apijet, and ServeFed won competitive awards for IT licenses, injectors, and health services, with $22M-$14M unobligated options signaling execution upside through 2027-2029.
- Deloitte/FDA BPA offers $3M option expansion(MEDIUM)▲
Deloitte's $14M obligated BPA for budget support has $3M options to $17M ceiling, extendable to 2027, amid full competition win.
- Acumen CMS TEAM model unlocks $43M options(MEDIUM)▲
Acumen's cost-plus deal for 5-year health model has $56.9M ceiling vs. $13.6M obligated, with potential to 2033.
Risk Flags(3)
- Execution[HIGH RISK]▼
Firm fixed price in 7/9 contracts risks cost overruns as contractors bear inflation/labor hikes through 2027+ tails.
- Market[MEDIUM RISK]▼
Unexercised options cap upside at ~$80M across deals; only 34% average remaining value post-outlays.
- Regulatory[LOW RISK]▼
Nonprofit/small biz dominance (6/9) limits equity investability; foreign-owned utility exposure in Washington Gas.
Opportunities(3)
- ◆
Option exercises could add $80M+ revenue, led by Acumen ($43M), Four Points ($22M), ServeFed ($14M).
- ◆
Long-term CMS models (TEAM, QIN-QIO, patient safety) extend to 2029-2033, favoring R&D/consulting repeat awards.
- ◆
Low outlay contracts like NORC ($11.6M, 0% disbursed) offer entry before 2025-2027 execution ramps.
Sector Themes(3)
- ◆
NIH/CMS prioritize IT licenses (Four Points), models (Acumen), surveys (NORC), with $85M+ extending to 2033.
- ◆
Apijet's COVID injector transition to HHS/ASPR through 2027 signals post-pandemic supply chain reliance.
- ◆
Washington Gas/Deloitte secure $65M near-term revenue despite 80%+ outlays, via non-competitive/BPA paths.
Watch List(3)
- 👁
{"entity"=>"Acumen LLC", "reason"=>"$56.9M ceiling vs. $13.6M obligated in CMS TEAM model to 2033 offers highest relative upside.", "trigger"=>"Option exercises >$20M or extension beyond 2027"}
- 👁
{"entity"=>"Four Points Technology", "reason"=>"SDVOSB IT win with $22.5M options, 70% outlayed toward 2025 end.", "trigger"=>"Full option obligation signaling $72M realization"}
- 👁
{"entity"=>"Apijet Systems", "reason"=>"Small biz med mfg with HHS transition and $6.6M remainder to 2027.", "trigger"=>"Follow-on non-competed awards"}
Get daily alerts with 3 investment signals, 3 risk alerts, 3 opportunities and full AI analysis of all 9 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC